HUTCHMED says China regulator accepts sovleplenib NDA for wAIHA, grants priority review

• China’s NMPA accepted sovleplenib’s NDA for adult warm autoimmune hemolytic anemia, granting priority review.
• Filing targets patients with inadequate response to at least one prior glucocorticoid treatment; Breakthrough Therapy Designation granted in March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260612-12200092), on June 12, 2026, and is solely responsible for the information contained therein.